Your search for tofacitinib returned 94 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Post remove
Older than 2 years remove
Home remove

Your search for tofacitinib returned 94 results

Sort Results:

Relevant Recent
Drug Monograph Updates

January 2020 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
News

Xeljanz XR Approved for Ulcerative Colitis

The FDA has approved Xeljanz XR (tofacitinib extended-release; Pfizer) for the treatment of adult patients with moderately to severely active ulcerative colitis.
AIBD 2019

Combination Biologics or Small Molecules vs Biologic Monotherapy in IBD

The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
AIBD 2019

Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis

In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
AIBD 2019

Case Highlights Novel Approach to Treatment of UC, Psoriatic Arthritis

A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.